Final Day to Invest
Surgery Will Never be the Same
Our precision robotic surgical assistants and FDA-approved, personalized knee implants are changing the way surgery is done forever. With over 14 patents in progress, our innovations are protected from imitators. Read on to learn how you stand to benefit as an investor.
Min. Investment
Share Price
Valuation
Min. Investment
Share Price
Valuation
NASDAQ Here We Come. Meet MGRM.
We’ve reserved the Monogram stock ticker - MGRM - a key step in our journey to going public*. In the meantime, our current private round remains open.
What People are Saying






A Broken Industry
Joint replacement technology is mostly the same today as it was 40 years ago. Surgeons use crude instruments like hand saws and jigs to prepare the bone for rigid, generic implants. No wonder the results are so bad.
- Over 100,000 knee replacements fail each year
- Up to ⅓ of patients have chronic pain after an implant surgery
- Instability, malalignment, and failure of fixation cause 50% of early revision surgeries
Robots in the Operating Room
Surgery is an incredibly invasive stressful process. Our surgical robots precisely create a digital map of a patient and make as minimal incisions as possible alongside surgeons to create a better surgery experience.
In fact, this year we held a live demonstration where a Monogram robot successfully operated on a cadaver alongside a surgeon in front of a virtual audience of over 5,000 people.
What makes the Monogram robot so effective?
- 7 degrees of freedom to boost range of motion
- Closed loop tracking
- Active navigated milling gently clears space for the implant
The World Deserves Personalized Implants
You wouldn’t wear a one size fits all shoe, so why would you accept a one size fits all knee replacement? You wouldn’t, but people have accepted this as the standard for years.
We aim to change this. Our implants are patient optimized and designed to meet individual patient’s anatomy as closely as possible. The result is a decrease in micro mobility which increases likelihood of acceptance of the implant by a patient.
The Knee Replacement Market is $19.6B
By 2027, 50% of all knee replacements will be robotic. We aim to have the first active navigated robotic arm on the market. If we are able to succeed we will capture a fraction of this massive market
Meet the Team

Douglas Unis, Md
Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.

Benjamin Sexson - CEO
Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.

Paul Riss
Experienced executive with a demonstrated history of completing SEC filings, focusing on the Securities Exchange Act of 1934 and Section 4(a)(6) of the Securities Act of 1933. Currently serves as a Director for NetCapital and was a CPA with Ernst & Young.

Kamran Shamaei, PhD
Kamran Shamaei received a Ph.D. from Yale University and MSc from ETH Zurich and did his postdoctoral research at Stanford University, focusing on Medical Robotics. He has extensive experience developing FDA cleared surgical robots.

Christopher Scifert, PhD
Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.


Kevin Posey

Muhammad Afnan

Sophia Sangiorgio, PhD

Laura Gilmour

Matt DiCicco, M.S.

Dr. Roshan Shah

Robert Jamieson

Dr. Matthew E. Heinrich

Darwin Chen

Join the Discussion